Latest news with #10YearHealthPlan
Business Upturn
27-05-2025
- Health
- Business Upturn
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
London, United Kingdom: This partnership launches a large-scale, AI-powered service designed to accelerate cancer detection and treatment using medical imaging in the UK's National Health Service (NHS) The Royal Marsden NHS Foundation Trust is ranked among world's top cancer research centers Marks a milestone in the application of artificial intelligence for cancer research and clinical innovation The Royal Marsden NHS Foundation Trust , a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA , a global leader in digital business and technology services, and , a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Professor Mike Lewis, NIHR Scientific Director for Innovation, said: 'Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. 'This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Wire
27-05-2025
- Business
- Business Wire
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
LONDON--(BUSINESS WIRE)-- The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Professor Mike Lewis, NIHR Scientific Director for Innovation, said: "Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. "This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual.
Daily Mirror
19-05-2025
- Health
- Daily Mirror
Warning over 'worrying' surge in health problem killing 420 people a week
People's heart health in the UK has declined more quickly at the start of the 2020s than any other decade for more than 50 years, figures suggest. Analysis by the British Heart Foundation (BHF) found rising deaths among working-age adults from cardiovascular disease, increasing heart failure and growing risks from obesity and diabetes. Cardiovascular deaths in working age adults have risen by 18% since 2019, from 18,693 to 21,975 in 2023, averaging 420 a week. Since 2020, the BHF has found a 'worrying trend', including: The new analysis also shows an 83% increase in people waiting for planned heart hospital treatment in England, from 232,082 at the start of the decade to 425,372 in March 2025. Cardiac waiting lists have also grown in Scotland, Wales and Northern Ireland. The BHF said the shift follows decades of progress to nearly halve annual deaths from conditions such as heart attack and stroke since the 1960s. It said issues such as an increasingly unhealthy population, widening health inequalities, the impact of Covid, pressure on the NHS and a lack of action over the last decade have all had an effect. Launching a new strategy, the BHF said focusing investment in areas such as artificial intelligence (AI), data science and genomics could help revolutionise how the UK prevents and treats cardiovascular disease. Dr Charmaine Griffiths, chief executive of the charity, said: 'It's been the worst start to a decade for heart health for half a century, but we're entering an era of immense scientific opportunity that can turn this tide. 'By driving a research revolution, we can reverse this worrying trend and save more lives than ever before. The BHF's new strategy will be key to this, and the next step for us as we aim to save many more families the heartbreak of losing loved ones far too soon.' Professor Bryan Williams, chief scientific and medical officer at the BHF, said: 'We need to act now to prevent the hard-won progress of recent decades being lost for future generations. Reimagining how we prevent and treat heart disease and stroke is key to transforming the nation's health. 'Research and innovation are how we'll achieve this, and the rapid advances in AI, data science, technology and advanced therapies offer us a glimpse into what's possible if we capitalise on this era of scientific opportunity. 'We can't do this alone, so support from governments and partners will be critical to unleash the potential of the UK's life sciences sector to help unlock the lifesaving treatments and cures millions are still waiting for.' By 2035, the charity wants the UK to prevent 125,000 heart attacks and strokes, reduce early deaths from cardiovascular disease by 25%, and cut the number of years lost to heart-related ill health by 25% by 2035. A Department of Health and Social Care spokesperson said: 'We welcome this new strategy from the British Heart Foundation and value their contribution to our upcoming 10 Year Health Plan. 'We are tackling the root causes of poor heart health by clamping down on smoking and obesity, as part of our Plan for Change to shift care from sickness to prevention. 'We are also delivering more tests and scans in the community, alongside greater use of technology to help people manage their conditions closer to home and reduce hospital admissions.'
North Wales Chronicle
15-05-2025
- Health
- North Wales Chronicle
Expand volunteer programme to bolster NHS workforce, charity says
The move could help with staffing problems in the health service as well as slashing the cost of relying on agencies that supply temporary staff, experts said. The Volunteer to Career programme has been piloted by the charity Helpforce in 48 NHS organisations across England. It provides training, mentorship and support to help volunteers transition to professional roles. Helpforce is now urging the Government to consider the scheme as part of its upcoming 10 Year Health Plan, claiming it could help fill around 23,600 frontline vacancies and related study placements by the end of the current Parliament in 2029. According to the charity, around 107,000 NHS secondary care roles in England are vacant and the annual cost of using agency and bank staff has topped £10 billion. Amerjit Chohan, chief executive of Helpforce, said: 'The success of the Volunteer to Career programme to date has been significant. 'Together with our partners in NHS trusts and other organisations, we've helped people who are interested in healthcare careers but don't have a background in the field to gain valuable experience before applying for paid roles. 'Through expertly designed and structured pathways, volunteers can find their niche without the immediate pressure of employment, while being upskilled and given confidence to take into job interviews. 'Since we launched the pilot initiative in 2022, hundreds of people have taken part, with 55% of them successfully transitioning from volunteering roles to paid careers in healthcare or associated courses – such as in nursing and midwifery. 'Our analysis shows that with the right investment, there's clear potential to supersize the opportunity, with conservative capacity for each of the 215 NHS trusts in England to support an average of 50 volunteers annually. 'We urge the Government to consider Volunteer to Career expansion within its upcoming NHS 10-Year Health Plan, unleashing the potential of home-grown healthcare talent.' It comes after Prime Minister Sir Keir Starmer set out a number of measures to help bring down immigration on Monday. The White Paper includes plans to end care worker visas for overseas recruitment. Think tanks the King's Fund and the Health Foundation have backed Helpforce's call to the Government. Dr Jennifer Dixon, Health Foundation chief executive, said the results of the pilot have been 'significant' and scaling it up ' has to be worthy of serious consideration by a government that's eager to get people back to work'. Sarah Woolnough, chief executive of the King's Fund, added: 'At a time when the NHS is severely stretched and tackling long-standing and chronic workforce shortages, Helpforce is doing excellent, innovative work to support volunteers to explore opportunities for an NHS career. 'To implement Volunteer to Career on a mass scale would require strategic investment in volunteer managers across NHS Trusts, but such investment would likely be cost-effective when set against paying high fees to agencies that supply temporary staff and helping to reduce the health services' reliance on recruiting large numbers of healthcare staff from overseas.'
Glasgow Times
15-05-2025
- Health
- Glasgow Times
Expand volunteer programme to bolster NHS workforce, charity says
The move could help with staffing problems in the health service as well as slashing the cost of relying on agencies that supply temporary staff, experts said. The Volunteer to Career programme has been piloted by the charity Helpforce in 48 NHS organisations across England. It provides training, mentorship and support to help volunteers transition to professional roles. Helpforce is now urging the Government to consider the scheme as part of its upcoming 10 Year Health Plan, claiming it could help fill around 23,600 frontline vacancies and related study placements by the end of the current Parliament in 2029. According to the charity, around 107,000 NHS secondary care roles in England are vacant and the annual cost of using agency and bank staff has topped £10 billion. Amerjit Chohan, chief executive of Helpforce, said: 'The success of the Volunteer to Career programme to date has been significant. 'Together with our partners in NHS trusts and other organisations, we've helped people who are interested in healthcare careers but don't have a background in the field to gain valuable experience before applying for paid roles. 'Through expertly designed and structured pathways, volunteers can find their niche without the immediate pressure of employment, while being upskilled and given confidence to take into job interviews. 'Since we launched the pilot initiative in 2022, hundreds of people have taken part, with 55% of them successfully transitioning from volunteering roles to paid careers in healthcare or associated courses – such as in nursing and midwifery. 'Our analysis shows that with the right investment, there's clear potential to supersize the opportunity, with conservative capacity for each of the 215 NHS trusts in England to support an average of 50 volunteers annually. 'We urge the Government to consider Volunteer to Career expansion within its upcoming NHS 10-Year Health Plan, unleashing the potential of home-grown healthcare talent.' It comes after Prime Minister Sir Keir Starmer set out a number of measures to help bring down immigration on Monday. The White Paper includes plans to end care worker visas for overseas recruitment. Think tanks the King's Fund and the Health Foundation have backed Helpforce's call to the Government. Dr Jennifer Dixon, Health Foundation chief executive, said the results of the pilot have been 'significant' and scaling it up ' has to be worthy of serious consideration by a government that's eager to get people back to work'. Sarah Woolnough, chief executive of the King's Fund, added: 'At a time when the NHS is severely stretched and tackling long-standing and chronic workforce shortages, Helpforce is doing excellent, innovative work to support volunteers to explore opportunities for an NHS career. 'To implement Volunteer to Career on a mass scale would require strategic investment in volunteer managers across NHS Trusts, but such investment would likely be cost-effective when set against paying high fees to agencies that supply temporary staff and helping to reduce the health services' reliance on recruiting large numbers of healthcare staff from overseas.'
